AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01400217 — intervention group
Intervention type: DRUG
Intervention: extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
Description: IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
Study NCT03896919 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: HLA-DQ by luminex technology in kidney transplantation
Description: HLA typing (DQ) for donor and recipient using Luminex microbead method from EDTA blood sample
Study NCT01409018 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: pharmacokinetics
Study NCT03151993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase
Description: 10 mg of drug reconstituted in 10 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
Study NCT03151993 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alteplase
Description: Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
Study NCT00031837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dalteparin
Study NCT04408469 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online EQuIP
Description: This online CBT treatment consists of 10 weekly modules that participants will complete over the course of 10 weeks.
Study NCT04408469 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Self-monitoring control
Description: Participants will be asked to indicate their past 7-day mood; stress experiences; and mental and behavioral health on an online survey experience once per week for 10 weeks
Study NCT01400217 — intervention group
Intervention type: DRUG
Intervention: standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler
Description: IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
Study NCT02342275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
Study NCT00120393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: atazanavir/ritonavir +2 NRTIs (immediate Switch Group)
Description: Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.
Study NCT00120393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LPV/r +2 NRTIs (Delayed/optional Switch Group)
Description: Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
Study NCT03788486 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 2-3 Joule LED blue light device
Description: application of blue light LED light device for 2 minutes in the central lower lids, temporal lower lids and upper temporal lids twice weekly under observation for one month
Study NCT00031837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00031837 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Study NCT02665611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention for improvement of adherence
Description: intervention for improvement of adherence
Study NCT00244738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Castor oil
Description: Patients who received castor oil for labor induction
Study NCT00244738 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil
Description: Patients who received sunflower oil as a placebo
Study NCT02665611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: treatment as usual
Description: The control group will be treated according to the usual stadard of care.
Study NCT03088384 — intervention group
Intervention type: DRUG
Intervention: Ketamine
Description: Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
Study NCT02342275 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atenolol
Description: Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
Study NCT02100189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cytology Specimen Collection Procedure
Description: Undergo esophageal cytology collection
Study NCT02100189 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Esophagogastroduodenoscopy
Description: Undergo standard EGD or endoscopy
Study NCT02100189 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02721420 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: dihydroartemisinin-piperaquine
Study NCT02721420 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: message(SMS) reminder
Study NCT02721420 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Health worker reminder
Description: Health surveillance assistants reminders prior to each treatment course
Study NCT02721420 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: short message(SMS) reminder
Study NCT02137928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin periocular injection
Description: 20mg/2ml carboplatin periocular injection together with chemotherapy
Study NCT02460991 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEB-TACE
Study NCT02460991 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Study NCT00273611 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pharmacist Education about Vitamin D
Study NCT04183933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pilates Exercise
Description: Pilates exercises will be given for 6 weeks, 3 days in a week.
Study NCT02137928 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy
Description: Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
Study NCT00360971 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: palifermin
Description: Four doses of palifermin, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
Study NCT04183933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Exercise
Description: Combined exercise will be given for 6 weeks, 3 days in a week.
Study NCT01224262 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
Description: A single vaccination of Fluzone alone
Study NCT01224262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)
Description: A single vaccination of Fluzone alone
Study NCT00360971 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
Study NCT01224262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIQ001 (0.45mg)
Description: A single vaccination of 0.45 mg LIQ001
Study NCT01224262 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: LIQ001 (1.8mg)
Description: A single vaccination of 1.8 mg LIQ001
Study NCT02358577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: In-bed cycling
Description: In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
Study NCT02358577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
Study NCT04020510 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onaBoNT-A
Description: Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
Study NCT04020510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: onaBoNT-A
Description: Intradetrusor onabotulinumtoxinA in either the standard number of injections or a reduced number of injections
Study NCT02546544 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Linsitinib
Study NCT00863850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bendamustine
Description: Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled \[14C\] bendamustine will be given on day 1 of cycle 1 only.
Study NCT02810535 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Observation
Description: Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE
Study NCT02810535 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Observation
Description: Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE
Study NCT02810535 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation
Description: Visit 1:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Completion of a Health Questionnaire~* Lung function testing with spirometry~* Skin prick test~Visit 2:~* Physical examination (inspection of nasopharynx, auscultation of heart and lungs)~* Measurement of nitric oxide in expired air (FeNO)~* Taking nasal secretion samples with a cotton carrier for 15 min~* Nasal provocation test with dust mite~* Blood sample collection to define blood count, IgE and specific IgE
Study NCT00434057 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: MelaFind(R)
Description: Biopsy ratio comparison
Study NCT00798798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Externally Implantable Tissue Expansion Device
Description: Will Apply Externally Implantable Tissue Expansion Device for 2 Days
Study NCT01301963 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: plerixafor
Description: Given SC
Study NCT01301963 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given SC
Study NCT01301963 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given SC
Study NCT03854344 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine Hydrochloride
Description: Injected subcutaneously for skin graft harvesting
Study NCT03854344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal bupivacaine
Description: Injected subcutaneously for skin graft harvesting
Study NCT03854344 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Hydrochloride
Description: Used for regional nerve block for skin graft harvesting
Study NCT02090738 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetazolamide group
Study NCT02090738 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard regimen group
Study NCT00360971 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cisplatin
Description: Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
Study NCT00360971 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Four doses of placebo, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
Study NCT01525290 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alteplase
Description: Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion
Study NCT01525290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: lyophilised powder to be reconstituted as solution indistinguishable from the active drug
Study NCT01058200 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: iCup
Description: new vacuum extractor: sterile disposable plastic cup
Study NCT04466696 — intervention group
Intervention type: BEHAVIORAL
Intervention: ERAS protocol
Description: items of ERAS protocol applied
Study NCT01058200 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: reference cup
Description: reference cup of the obstetrical ward: metallic cup
Study NCT05717088 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 24% Sucrose solution
Description: Infants will either receive oral sucrose (24%) 2 minutes before the procedure LUS scan. The dose will be 0.2 mL, 0.5 mL and 1 mL for infants with current weight \< 1500g, 1500-2500g, and > 2500g respectively.
Study NCT02619734 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Infusion of Autologous Bone Marrow Mononuclear Cells
Description: Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.
Study NCT01488799 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Motivational Interviewing and Cognitive Behavioural Therapy
Description: Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
Study NCT00559559 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ICD implant + Patient Notifier turned OFF
Description: ICD implant, plus standard care, i.e. Patient Notifier turned off
Study NCT00559559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ICD Implant + Patient Notifier turned ON
Description: ICD implant. The Patient Notifier™ feature will be turned ON.
Study NCT01197950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Manual Acupuncture
Description: The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
Study NCT01197950 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro Acupuncture
Description: The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
Study NCT00731315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computer-assisted treatment group
Description: This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
Study NCT00731315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care group
Description: This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
Study NCT00941239 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin ER
Description: 850mg daily for 30 days
Study NCT00941239 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin
Description: 850 mg daily for 30 days
Study NCT02308436 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Candida Mouthwash with Curolox™ Peptide
Description: Prophylaxis - protection and care of teeth against caries \& acidic challenges
Study NCT03418844 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-questionnaires of living conditions and quality of life
Description: Patients will complete self-questionnaires of living conditions and quality of life (MFI-20, FACT-G/FACT-O, FACT/COG-NTX, FACT-Cog, HADS, Insomnia Severity Index , International Physical Activity Questionnaire)
Study NCT03418844 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac, pulmonary, auditory and biological assessment
Description: Patients will perform :~* Cardiac assesments (ECG, Carotid and humeral Doppler ultrasound, Trans-thoracic echocardiography 2D and 3D)~* Pulmonary and auditory assesment ( Respiratory Functional Exploration, Tonal audiogram)~* Blood tests
Study NCT01960413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast added to Hydroxyurea
Study NCT03568526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Attend a therapy session
Study NCT03568526 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Complete exercise
Study NCT03568526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03568526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT03568526 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies
Study NCT01960413 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo added to Hydroxyurea
Study NCT01529957 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
Study NCT02083588 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dTMS
Description: All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
Study NCT01529957 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nemonoxacin Malate Sodium Chloride
Description: Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
Study NCT00360971 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neck dissection
Description: A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
Study NCT01206335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OHR/AVR118
Description: OHR/AVR118 given subcutaneously at 4mL per day
Study NCT01506739 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil Hydrochloride
Description: Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.